Study Evaluating Sirolimus in Kidney Transplant Recipients in India

Back to Search
Print
Bookmark Trial

NCT00195481

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Bangalore, Karnataka, 566 006, India
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Kidney Failure, Graft vs Host Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
13 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients in End Stage Renal Disease who are above 13 years of age and weigh more than 40 kilograms.

- Patients scheduled to receive a kidney from a cadaveric donor, from a living unrelated donor or from a living related donor.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Evidence of major infections at the time of sirolimus administration


- Use of any investigational drug or treatment up to 4 weeks prior to enrolling in the
study and during the treatment phase.


- Females who are pregnant, breast feeding or in reproductive age group and not using a
medically acceptable form of contraception

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Kidney Failure, Graft vs Host DiseaseStudy Comparing Cyclosporine Dose Reduction vs. Cyclosporine Elimination in Kidney Transplant Recipients Taking Sirolimus
NCT00195468
  1. Curitiba, PR
  2. Rio de Janeiro, RJ
  3. Rio de Janeiro, RJ
  4. Porto Alegre, RS
  5. Porto Alegre, RS
  6. Ribeirao Preto, RS
  7. Sao Jose do Rio Preto, SP
  8. Sao Paulo, SP
  9. Sao Paulo, SP
  10. Sao Paulo, SP
  11. Torreon, Coahuila
  12. Chihuahua,
  13. Mexico City DF,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Kidney Failure, Graft vs Host DiseaseA Study Comparing the Withdrawal of Steroids or Tacrolimus in Kidney Transplant Recipients
NCT00195429
  1. Sao Paulo,
ALL GENDERS
13 Years+
years
MULTIPLE SITES
Kidney Failure, Graft vs Host DiseaseStudy Evaluating Sirolimus in Kidney Transplant Recipients in India
NCT00195481
  1. Bangalore, Karnataka
  2. Bangalore, Karnataka
  3. Saket, South Delhi
  4. Chennai, Tamil Nadu
  5. New Delhi,
ALL GENDERS
13 Years+
years
MULTIPLE SITES
Kidney Failure, Graft vs Host DiseaseStudy Evaluating Sirolimus in Kidney Transplant Recipients.
NCT00167947
  1. Roma, Lazio
  2. Roma, Lazio
  3. Palermo, Sicily
  4. Bari,
  5. Bologna,
  6. Cagliari,
  7. Firenze,
  8. L'Aquila,
  9. Milano,
  10. Pisa,
  11. Sassari,
  12. Siena,
  13. Udine,
  14. Varese,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study Evaluating Sirolimus in Kidney Transplant Recipients in India
Official Title  ICMJE A Post Marketing Surveillance Looking at Safety of Rapamune (Sirolimus) in Indian Population Undergoing de Novo Renal Transplantation.
Brief Summary To determine the safety of sirolimus tablets in renal allograft recipients in a postmarketing surveillance setting.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Kidney Failure
  • Graft vs Host Disease
Intervention  ICMJE Drug: Rapamune
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE
 (submitted: September 13, 2005)		100
Original Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE December 2005
Actual Primary Completion Date December 2005   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients in End Stage Renal Disease who are above 13 years of age and weigh more than 40 kilograms.
  • Patients scheduled to receive a kidney from a cadaveric donor, from a living unrelated donor or from a living related donor.

Exclusion Criteria:

  • Evidence of major infections at the time of sirolimus administration
  • Use of any investigational drug or treatment up to 4 weeks prior to enrolling in the study and during the treatment phase.
  • Females who are pregnant, breast feeding or in reproductive age group and not using a medically acceptable form of contraception
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 13 Years and older   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE India
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00195481
Other Study ID Numbers  ICMJE 0468H-101543
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth
Study Sponsor  ICMJE Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Medical MonitorWyeth is now a wholly owned subsidiary of Pfizer
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date December 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP